Vicebio secures $100m to advance RSV and hMPV vaccine combo …
WEB2 days ago · Vicebio will also use the funds to develop VXB-251, a trivalent vaccine targeting RSV, hMPV, and parainfluenza virus 3 (PIV3). Both VXB-241 and VXB-251 have been developed with Vicebio’s ...
Vicebio Announces $100 Million Series B Financing and Initiation …
WEB2 days ago · Vicebio has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting both RSV and hMPV viruses that cause a significant burden of disease in elderly patients and ...
Vicebio closes $100m financing round to advance multivalent …
WEB22 hours ago · London-based biopharmaceutical company Vicebio has announced a $100 million series B financing led by TCGX and with the participation of Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest and Medicxi. Vicebio is developing next-generation vaccines that target a wide range of respiratory viruses, including respiratory syncytial virus ...
Vicebio secures $100m to advance RSV and hMPV vaccine combo …
WEB1 day ago · UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including respiratory syncytial virus (RSV) to Phase I trials. Vicebio is the latest biotech to eye up the RSV market, a space that has seen a buzz of development over the last year.
Vicebio Announces $100 Million Series B Financing and Initiation …
WEB21 hours ago · London, UK - Vicebio Ltd ('Vicebio'), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi.. Vicebio is developing next-generation vaccines for ...
Vicebio hauls in $100M series B to push RSV shot through phase 1
WEB5 days ago · The British biotech has secured $100 million in series B funds as it continues a phase 1 trial of its bivalent vaccine targeting both RSV and human metapneumovirus (hMPV). A readout for the ...
Startup Vicebio banks $100M in bid to make ‘cost-effective’ …
WEB2 days ago · Vicebio, a London-based biotechnology startup, has raised $100 million in Series B financing to continue developing a technology it claims has the potential to produce potent vaccines that are easy to manufacture. The Series B round announced Monday was led by new backer TCGX and involved Goldman Sachs Alternatives, Avoro Ventures and founding ...
Vicebio launched by medicxi to advance the Molecular Clamp …
WEBJul 21, 2022 · Vicebio is advancing its proprietary, second-generation Molecular Clamp technology capable of stabilising viral glycoproteins in "prefusion" conformation, to deliver highly protective and...
Vicebio raises $100 million for next-gen respiratory virus vaccines
WEB2 days ago · British biotech Vicebio has secured $100 million in a series B funding round to advance its next-generation vaccines against respiratory viruses. The company’s bivalent vaccine, VXB-241, targets respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). A Phase I trial has begun, with results expected by mid-2025.
$100 Million Funds RSV/hMPV Bivalent Vaccine Candidate
WEB1 day ago · September 23, 2024 • 9:13 am CDT. from Pixabay. (Precision Vaccinations News) Vicebio Ltd. today announced a $100 million Series B financing led by TCGX and others. Vicebio is developing next-generation vaccines for respiratory viruses utilizing its proprietary Molecular Clamp technology, which was discovered at the University of Queensland (UQ).